YDES (YD Bio) Shares Outstanding (EOP): 70.79 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

YDES YD Bio Ltd YDES
12 GF Score
Price $2.15
! 1 Warning Sign
View Full Analysis

What is YD Bio Shares Outstanding (EOP)?

YD Bio YDES -3.59% 12 Shares Outstanding (EOP) is 70.79 Mil as of Dec. 2025. GuruFocus rates YDES with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. YD Bio's shares outstanding for the quarter that ended in Dec. 2025 was 70.79 Mil.

YD Bio's quarterly shares outstanding increased from Jun. 2025 (70.10 Mil) to Dec. 2025 (70.79 Mil). It means YD Bio issued new shares from Jun. 2025 to Dec. 2025 .

YD Bio's annual shares outstanding increased from Dec. 2024 (70.10 Mil) to Dec. 2025 (70.79 Mil). It means YD Bio issued new shares from Dec. 2024 to Dec. 2025 .


YD Bio  (NAS:YDES) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


YD Bio Shares Outstanding (EOP) Related Terms


YD Bio Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for YD Bio's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

YD Bio Shares Outstanding (EOP) Chart

YD Bio Annual Data
Trend Dec23 Dec24 Dec25
Shares Outstanding (EOP)
70.10 70.10 70.79

YD Bio Semi-Annual Data
Dec24 Jun25 Dec25
Shares Outstanding (EOP) 70.10 70.10 70.79

YDES vs CRBU, ABOS, PRQR: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, YD Bio's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


YD Bio Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, YD Bio's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where YD Bio's Shares Outstanding (EOP) falls into.


YDES
12GF Score
YD Bio Ltd YDES
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

YD Bio Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 70.79 Mil mean?
YD Bio (YDES) has a Shares Outstanding (EOP) of 70.79 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on YD Bio and its competitors.
Is YD Bio's Shares Outstanding (EOP) too high?
YD Bio's current Shares Outstanding (EOP) is 70.79 Mil. Overall, YD Bio has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does YD Bio's Shares Outstanding (EOP) compare to CRBU and ABOS?
YD Bio's Shares Outstanding (EOP) of 70.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on YD Bio and its competitors. YD Bio's current Shares Outstanding (EOP) is 70.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is YD Bio stock overvalued right now?
YD Bio (YDES) has a current Shares Outstanding (EOP) of 70.79 Mil. The current Shares Outstanding (EOP) is 70.79 Mil. YD Bio's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For YD Bio (YDES), the current Shares Outstanding (EOP) is 70.79 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

YD Bio Business Description

Address No. 3, Xingnan Street, 12th Floor, Nangang District, Taipei City, TWN, 115001
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
12GF Score

Get the complete analysis for YDES

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.15
Price